New treatment methods for myocardial infarction

Bingbing Sun; Long Wang; Wenmin Guo; Shixuan Chen; Yujie Ma; Dongwei Wang

doi:10.3389/fcvm.2023.1251669

New treatment methods for myocardial infarction

Front Cardiovasc Med. 2023 Sep 28:10:1251669. doi: 10.3389/fcvm.2023.1251669. eCollection 2023.

Authors

Bingbing Sun^#¹, Long Wang^#², Wenmin Guo¹, Shixuan Chen³, Yujie Ma¹, Dongwei Wang⁴

Affiliations

¹ Department of Critical Care Medicine, The Air Force Characteristic Medical Center, Air Force Medical University, Beijing, China.
² Department of General Internal Medicine, Beijing Dawanglu Emergency Hospital, Beijing, China.
³ Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, China.
⁴ Department of Cardiac Rehabilitation, Zhengzhou Central Hospital affiliated to Zhengzhou University, Zhengzhou, China.

^# Contributed equally.

Abstract

For a long time, cardiovascular clinicians have focused their research on coronary atherosclerotic cardiovascular disease and acute myocardial infarction due to their high morbidity, high mortality, high disability rate, and limited treatment options. Despite the continuous optimization of the therapeutic methods and pharmacological therapies for myocardial ischemia-reperfusion, the incidence rate of heart failure continues to increase year by year. This situation is speculated to be caused by the current therapies, such as reperfusion therapy after ischemic injury, drugs, rehabilitation, and other traditional treatments, that do not directly target the infarcted myocardium. Consequently, these therapies cannot fundamentally solve the problems of myocardial pathological remodeling and the reduction of cardiac function after myocardial infarction, allowing for the progression of heart failure after myocardial infarction. Coupled with the decline in mortality caused by acute myocardial infarction in recent years, this combination leads to an increase in the incidence of heart failure. As a new promising therapy rising at the beginning of the twenty-first century, cardiac regenerative medicine provides a new choice and hope for the recovery of cardiac function and the prevention and treatment of heart failure after myocardial infarction. In the past two decades, regeneration engineering researchers have explored and summarized the elements, such as cells, scaffolds, and cytokines, required for myocardial regeneration from all aspects and various levels day and night, paving the way for our later scholars to carry out relevant research and also putting forward the current problems and directions for us. Here, we describe the advantages and challenges of cardiac tissue engineering, a contemporary innovative therapy after myocardial infarction, to provide a reference for clinical treatment.

Keywords: cardiac regenerative medicine; coronary heart disease; exosome; myocardial infarction; scaffold.

Publication types

Review